31 July 2021: Clinical Research
Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy
Xingqin Zhou 1BCE , Yazhou Chang 2BD , Jing Qian 1BF , Chaoyan Shen 1DEF , Jie Han 1EF , Hongyu Zhao 1DF , Renan Chang 3AG*DOI: 10.12659/MSM.929474
Med Sci Monit 2021; 27:e929474
Table 3 Area under the curve of 5-Fluorouracil concentration in blood (actual exposure) in every cycle.
| Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | |
|---|---|---|---|---|---|---|
| N | 54 | 54 | 50 | 47 | 44 | 40 |
| Mean | 19.3 | 21.9 | 24.8 | 26.3 | 26.3 | 26.8 |
| SD | 8.2 | 7.5 | 6.4 | 5.9 | 5.5 | 5.2 |
| Median | 17 | 23 | 24.5 | 28 | 26 | 26.5 |
| Range | 7–37 | 9–41 | 13–36 | 14–38 | 16–37 | 17–38 |
| CV | 42.4% | 34.2% | 25.7% | 22.4% | 21.0% | 19.4% |
| AUC ≤19 | 32 | 22 | 11 | 7 | 4 | 4 |
| 57.4% | 40.7% | 22.0% | 14.9% | 9.1% | 10.0% | |
| AUC 20–29 | 16 | 23 | 24 | 22 | 28 | 24 |
| 29.6% | 42.6% | 48.0% | 46.8% | 63.6% | 60.0% | |
| AUC ≥30 | 7 | 9 | 15 | 18 | 12 | 12 |
| 13.0% | 16.7% | 30.0% | 38.3% | 27.3% | 30.0% |